345953-43-7

Basic information

• Product Name: 2-bromo-4-(bromomethyl)benzaldehyde
• Synonyms: 2-bromo-4-(bromomethyl)benzaldehyde
• CAS NO: 345953-43-7
• Molecular Formula: C₈H₆Br₂O
• Molecular Weight: 277.94064
• Mol File: 345953-43-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-bromo-4-(bromomethyl)benzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 2-bromo-4-(bromomethyl)benzaldehyde(345953-43-7)
• EPA Substance Registry System: 2-bromo-4-(bromomethyl)benzaldehyde(345953-43-7)

Safety Data

• Hazardous Substances Data: 345953-43-7(Hazardous Substances Data)

Upstream product

• 345953-41-5 [2-bromo-4-(bromomethyl)phenyl]methanol 
• 345953-39-1 2-bromo-4-(bromomethyl)benzoic Acid 
• 7697-27-0 2-bromo-4-methylbenzoic acid 

Downstream Products

• 345953-45-9 di(tert-butyl) [2-bromo-4-(bromomethyl)phenyl](hydroxy)methylphosphonate 
• 1313041-76-7 4-difluoromethyl-3-pyridin-4-yl-benzylamine 
• 1313041-77-8 N-(4-difluoromethyl-3-pyridin-4-yl-benzyl)-2,2,2-trifluoro-acetamide hydrochloride 
• 1313041-78-9 N-(4-difluoromethyl-3-piperidin-4-yl-benzyl)-2,2,2-trifluoro-acetamide hydrochloride 
• 1313041-73-4 4-(azidomethyl)-2-bromobenzaldehyde 
• 1313041-74-5 4-azidomethyl-2-bromo-1-difluoromethyl-benzene 
• 1313041-75-6 3-bromo-4-difluoromethyl-benzylamine 
• 345953-48-2 di(tert-butyl)[2-bromo-4-(3-oxo-2,3-diphenylpropyl)phenyl](difluoro)methylphosphonate 
• 345953-47-1 di(tert-butyl)[2-bromo-4-(bromomethyl)phenyl] (difluoro)methylphosphonate 
• 345953-46-0 di-(tert-butyl)-2-bromo-4-(bromomethyl) benzoylphosphonate 

Relevant articles and documents

Protein tyrosine phosphatase 1B (PTP-1B) inhibitors containing two ortho-substituted aromatic phosphonates

The invention encompasses the novel class of compounds represented by formula I, which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions and methods of treating or preventing PTP-1B mediated diseases, including diabetes, obesity, and diabetes-related diseases.

The development of potent non-peptidic PTP-1B inhibitors

The SAR from our peptide libraries was exploited to design a series of potent deoxybenzoin PTP-1B inhibitors. The introduction of an ortho bromo substituent next to the difluoromethylphosphonate warhead gave up to 20-fold increase in potency compared to the desbromo analogues. In addition, these compounds were orally bioavailable and active in the animal models of non-insulin dependent diabetes mellitus (NIDDM).

Protein tyrosine phosphatase 1B (PTP-1B) inhibitors containing two ortho-substituted aromatic phosphonates

The invention encompasses the novel class of compounds represented by formula I, which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions and methods of treating or preventing PTP-1B mediated diseases, including diabetes, obesity, and diabetes-related diseases.

Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase IB (PTP-IB)

The invention encompasses the novel class of compounds represented by formula I which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions and methods of treating or preventing PTP-1B mediated diseases, including diabetes, obesity, and diabetes-related diseases.

Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B)

The invention encompasses the novel class of compounds represented by formula I, which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions and methods of treating or preventing PTP-1B mediated diseases, including diabetes, obesity, and conditions related to diabetes.

Protein tyrosine phosphatase 1B (PTP-1B) inhibitors containing two ortho-substituted aromatic phosphonates

The invention encompasses the novel class of compounds represented by formula I, which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions and methods of treating or preventing PTP-1B mediated diseases, including diabetes, obesity, and diabetes-related diseases.